口服地西他滨联合西达尿苷与维奈克拉治疗较高危骨髓增生异常综合征或慢性粒单核细胞白血病:单中心1/2期研究
这项单中心1/2期研究评估口服地西他滨联合西达尿苷与维奈克拉治疗初治较高危骨髓增生异常综合征或慢性粒单核细胞白血病(原始细胞>5%)的安全性和活性。39例患者中,最大耐受剂量未达到,推荐的2期剂量为口服地西他滨35mg联合西达尿苷100mg用5天及维奈克拉400mg用14天。总缓解率为95%(95%CI 83-99;37/39),49%患者后续接受造血干细胞移植。
要点
- 推荐的2期剂量为口服地西他滨35mg联合西达尿苷100mg用5天及维奈克拉400mg用14天
- 总缓解率为95%(95%CI 83-99;37/39)
- 3-4级不良事件最常见为血小板减少(85%)、中性粒细胞减少(74%)和发热性中性粒细胞减少(21%)
核心结论
- 早期分析提示,口服地西他滨联合西达尿苷与维奈克拉治疗较高危骨髓增生异常综合征和慢性粒单核细胞白血病在多数患者中安全,且活性令人鼓舞。
- 需要更长时间随访以确认这些数据。
研究设计与样本
- 单中心、剂量递增和剂量扩展的1/2期临床试验,纳入初治较高危骨髓增生异常综合征或慢性粒单核细胞白血病(国际预后评分系统风险等级为中危-2或更高)且原始细胞>5%的患者。
- 2021年1月21日至2023年1月20日共入组39例患者(1期9例,2期30例),中位年龄71岁(范围27-94),男性28例(72%),女性11例(28%)。
- 治疗为口服地西他滨35mg联合西达尿苷100mg第1-5天,维奈克拉100-400mg第1-14天,28天为一周期。
- 1期主要结局为安全性,2期主要结局为总缓解;试验正在进行,本次分析为非预设分析,注册号NCT04655755。
主要发现
- 最大耐受剂量未达到,推荐的2期剂量为口服地西他滨35mg联合西达尿苷100mg用5天及维奈克拉400mg用14天。
- 3-4级不良事件最常见为血小板减少33例(85%)、中性粒细胞减少29例(74%)和发热性中性粒细胞减少8例(21%)。
- 研究药物期间发生4例非治疗相关死亡,原因为脓毒症2例、肺部感染1例和原因不明1例。
- 中位随访时间10.8个月(IQR 5.6-16.4),总缓解率为95%(95%CI 83-99;37/39)。
- 19例(49%)患者后续接受造血干细胞移植。
临床怎么用
- 作者认为,对于较高危骨髓增生异常综合征和慢性粒单核细胞白血病,口服地西他滨联合西达尿苷与维奈克拉在多数患者中安全且活性令人鼓舞。
- 作者指出需要更长时间随访以确认这些数据。
局限性
- 本分析为非预设分析,试验仍在进行中。
- 作者指出需要更长时间随访以确认这些数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypomethylating agents are approved in higher-riskmyelodysplastic syndromes. The combination of a hypomethylating agent with venetoclax is standard of care in acute myeloid leukaemia. We investigated the safety and activity of the first totally oral combination of decitabine plus cedazuridine and venetoclax in patients with higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia. METHODS: We did a single-centre, dose-escalation and dose-expansion, phase 1/2, clinical trial. Patients with treatment-naive higher-risk-myelodysplastic syndromes or chronic myelomonocytic leukaemia (risk level categorised as intermediate-2 or higher by the International Prognostic Scoring System) with excess blasts (>5%). Treatment consisted of oral decitabine 35 mg plus cedazuridine 100 mg on days 1-5 and venetoclax (variable doses of 100-400 mg, day 1 to 14, 28-day cycle). The primary outcomes were safety for the phase 1 part and the overall response for the phase 2 part of the study. The trial is ongoing and this analysis was not prespecified. This study is registered with ClinicalTrials.gov, NCT04655755, and is currently enrolling participants. FINDINGS: Between Jan 21, 2021, and Jan 20, 2023, we enrolled 39 patients (nine in phase 1 and 30 in phase 2). The median age was 71 years (range 27-94), 28 (72%) patients were male, and 11 (28%) were female. The maximum tolerated dose was not reached, and the recommended phase 2 dose was established as oral decitabine 35 mg plus cedazuridine 100 mg for 5 days and venetoclax (400 mg) for 14 days. The most common grade 3-4 adverse events were thrombocytopenia (33 [85%] of 39), neutropenia (29 [74%]), and febrile neutropenia (eight [21%]). Four non-treatment-related deaths occurred on the study drugs due to sepsis (n=2), lung infection (n=1), and undetermined cause (n=1). The median follow-up time was 10·8 months (IQR 5·6-16·4). The overall response rate was 95% (95% CI 83-99; 37/39). 19 (49%) patients proceeded to hematopoietic stem-cell transplantation. INTERPRETATION: This early analysis suggests that the combination of oral decitabine plus cedazuridine with venetoclax for higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia is safe in most patients, with encouraging activity. Longer follow-up will be needed to confirm these data. FUNDING: MD Anderson Cancer Center, MDS/AML Moon Shot, Genentech/AbbVie, and Astex Pharmaceuticals.
引用
- Bataller A, Montalban-Bravo G, Bazinet A, et al. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024. PMID: 38316133. doi:10.1016/S2352-3026(23)00367-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。